242 related articles for article (PubMed ID: 16762146)
21. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD).
Bodolay E; Csiki Z; Szekanecz Z; Ben T; Kiss E; Zeher M; Szücs G; Dankó K; Szegedi G
Clin Exp Rheumatol; 2003; 21(3):313-20. PubMed ID: 12846049
[TBL] [Abstract][Full Text] [Related]
22. C1D is a major autoantibody target in patients with the polymyositis-scleroderma overlap syndrome.
Schilders G; Egberts WV; Raijmakers R; Pruijn GJ
Arthritis Rheum; 2007 Jul; 56(7):2449-54. PubMed ID: 17599775
[TBL] [Abstract][Full Text] [Related]
23. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma.
Maes L; Blockmans D; Verschueren P; Westhovens R; De Beéck KO; Vermeersch P; Van den Bergh K; Burlingame RW; Mahler M; Bossuyt X
Clin Chim Acta; 2010 Jul; 411(13-14):965-71. PubMed ID: 20346932
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma.
Foocharoen C; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2016 Sep; 19(9):913-23. PubMed ID: 27126733
[TBL] [Abstract][Full Text] [Related]
25. A Japanese patient with anti-PM/Scl and centromere antibody-positive scleroderma-amyopathic dermatomyositis overlap syndrome who developed renal crisis.
Nishida T; Nakano K; Satoh M; Fukuyo S; Akashi K; Tanaka Y
Mod Rheumatol Case Rep; 2022 Jan; 6(1):69-74. PubMed ID: 34506625
[TBL] [Abstract][Full Text] [Related]
26. Scleroderma overlap syndromes.
Jablonska S; Blaszczyk M
Adv Exp Med Biol; 1999; 455():85-92. PubMed ID: 10599327
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of autoantibody screening in patients with autoimmune myositis.
Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
[TBL] [Abstract][Full Text] [Related]
28. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
Hanke K; Brückner CS; Dähnrich C; Huscher D; Komorowski L; Meyer W; Janssen A; Backhaus M; Becker M; Kill A; Egerer K; Burmester GR; Hiepe F; Schlumberger W; Riemekasten G
Arthritis Res Ther; 2009; 11(1):R22. PubMed ID: 19220911
[TBL] [Abstract][Full Text] [Related]
29. Anti-Polymyositis/Scl Antibodies in Systemic Sclerosis: Clinical Associations in a Multicentric Spanish Cohort and Review of the Literature.
Iniesta Arandia N; Espinosa G; Guillén Del Castillo A; Tolosa-Vilella C; Colunga-Argüelles D; González de Echávarri Pérez de Heredia C; Lledó GM; Comet LS; Ortego-Centeno N; Vargas Hito JA; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Rodríguez-Carballeira M; Trapiella-Martínez L; Fonollosa-Pla V; Simeón-Aznar CP
J Clin Rheumatol; 2022 Jan; 28(1):e180-e188. PubMed ID: 33938499
[TBL] [Abstract][Full Text] [Related]
30. Scleroderma overlap syndromes.
Pope JE
Curr Opin Rheumatol; 2002 Nov; 14(6):704-10. PubMed ID: 12410095
[TBL] [Abstract][Full Text] [Related]
31. Immunoserological aspects of idiopathic inflammatory muscle disease.
Rozman B; Bozic B; Kos-Golja M; Plesivcnik-Novljan M; Kveder T
Wien Klin Wochenschr; 2000 Aug; 112(15-16):722-7. PubMed ID: 11020964
[TBL] [Abstract][Full Text] [Related]
32. [PM-Scl antibody positive systemic sclerosis associated with inclusion-body myositis].
Kim S; Genth E; Krieg T; Hunzelmann N
Z Rheumatol; 2005 Oct; 64(7):499-502. PubMed ID: 16244833
[TBL] [Abstract][Full Text] [Related]
33. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes.
Reimer G; Scheer U; Peters JM; Tan EM
J Immunol; 1986 Dec; 137(12):3802-8. PubMed ID: 3537125
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Kaji K; Fujimoto M; Hasegawa M; Kondo M; Saito Y; Komura K; Matsushita T; Orito H; Hamaguchi Y; Yanaba K; Itoh M; Asano Y; Seishima M; Ogawa F; Sato S; Takehara K
Rheumatology (Oxford); 2007 Jan; 46(1):25-8. PubMed ID: 16728436
[TBL] [Abstract][Full Text] [Related]
35. Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations.
Oddis CV; Okano Y; Rudert WA; Trucco M; Duquesnoy RJ; Medsger TA
Arthritis Rheum; 1992 Oct; 35(10):1211-7. PubMed ID: 1418007
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
Mahler M; Raijmakers R; Dähnrich C; Blüthner M; Fritzler MJ
Arthritis Res Ther; 2005; 7(3):R704-13. PubMed ID: 15899056
[TBL] [Abstract][Full Text] [Related]
37. Interstitial lung disease in polymyositis and dermatomyositis.
Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H
Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835
[TBL] [Abstract][Full Text] [Related]
38. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients.
Troyanov Y; Targoff IN; Tremblay JL; Goulet JR; Raymond Y; Senécal JL
Medicine (Baltimore); 2005 Jul; 84(4):231-249. PubMed ID: 16010208
[TBL] [Abstract][Full Text] [Related]
39. Clinical and serological hallmarks of systemic sclerosis overlap syndromes.
Pakozdi A; Nihtyanova S; Moinzadeh P; Ong VH; Black CM; Denton CP
J Rheumatol; 2011 Nov; 38(11):2406-9. PubMed ID: 21844148
[TBL] [Abstract][Full Text] [Related]
40. [A case of mixed connective tissue disease developed into overlap syndrome of progressive systemic sclerosis, systemic lupus erythematosus, polymyositis and Sjögren's syndrome].
Akiyama Y; Suzuki T; Tanaka M; Kobayashi K; Kagiri T; Ishibashi T; Kitagawa H; Imai F; Hara K; Doi Y
Arerugi; 1990 Jun; 39(6):542-7. PubMed ID: 2222196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
